Z51.5 F05.8 F05.9 F13.4
Conditions
Interventions
Group 1: All EPIC study patients in the participating Charité intensive care units (wards) should be offered participation in this accompanying scientific program by EPIC (https://clinicaltrials.gov/s
Sponsors
Charité-Universitätsmedizin Berlin, Klinik für Anästhesiologie und Intensivmedizin CCM/CVK
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Consent given and inclusion in the EPIC study at Charité • Patients capable of giving consent and those incapable of giving consent (via their authorized representative or guardian/spouse representative, also possible with delayed consent) • Patients in intensive care
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantification of protein expression from plasma in connection with delirium Time Frame: At the beginning of the investigation Proteome analysis can be used to identify biomarkers that indicate inflammation, organ failure, or other critical conditions. In the future, this information could potentially be used not only for diagnosis and prognosis, but also for monitoring disease progression and therapies. Proteome analyses from plasma samples are performed using mass spectrometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Additional biomarkers (of telomere structures, protein structures and at the level of immune cells) to detect extraordinary stress at the cellular/mitochondrial level: 1.a.Mitochondrial function of immune cells [Time Frame: At the beginning of the investigation] 1.b. Measurement of intracellular pH of immune cells [Time Frame: At the beginning of the investigation] 1.c. Determination of autophagy flux, Determination of immune cell function and Determination of metabolic markers [Time Frame: At the beginning of the investigation] 1.d. Detection of telomere length [Time Frame: At the beginning of the investigation] 1.e. Detection of gene expression [Time Frame: At the beginning of the investigation] 2. Clinical frailty scale [Time Frame: Up to three months] 3. Concomitant medication [Time Frame: At the beginning of the investigation] 4. Quality indicators for intensive care medicine (DIVI) [Time Frame: At the beginning of the investigation] 5. Basic palliative care assessment. (QI - palliative care) - including SAPV module [Time Frame: Up to three months] 6. Physical (quality of life score) and Mental health (stress thermometer) Physical (quality of life score) and mental helth are measured as Likert scale/VAS [Time Frame: Up to three months] 7. Mortality [Time Frame: Up to three months] | — |
Countries
Germany
Contacts
Public ContactClaudia Spies
Charité-Universitätsmedizin Berlin, Klinik für Anästhesiologie und Intensivmedizin CCM/CVK
Outcome results
None listed